Trial Profile

Efficacy and Safety of COVID-19 Vaccine in Patients After Allogeneic Hamatopoietic Cell Transplantation, CAR-T Therapy and With Primary Immune Deficiency - a Post Marketing Prospective Cohort Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2021 Results(n=79) assessing Safety and Efficacy of the Bnt162b2 Mrna Covid-19 Vaccine in Patients after Allogeneic Hct and Cd19-Based Car-T Therapy presented at the 26th Congress of the European Haematology Association
12 Jun 2021 According to a European Hematology Association media release, data from this study were presented at the European Hematology Association.
12 Jun 2021 Results presented in a European Hematology Association media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com